The size of APAC in Situ Hybridization Market in terms of revenue was estimated to be worth USD 363 million in 2022 and is poised to reach USD 744 million by 2027, growing at a CAGR of 15.4% from 2022 to 2027. The research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

In developed countries, high-quality molecular diagnostic tests are readily available. However, in developing countries, the cost of these diagnostic technologies is very high, which often makes them unaffordable for a large part of the population. Moreover, the lack of a commercial market for diagnostic procedures has resulted in the availability of a small number of diagnostic tests in developing countries. As a result, emerging markets such as India, China, and South Korea offer significant growth opportunities for MDx-based technologies (including ISH) owing to the rising geriatric population, the growing prevalence of infectious diseases and various types of cancers, the improving healthcare infrastructure, and increasing investments by respective government bodies and leading players in these countries.

Download the PDF Brochure at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51341505

Key Players:

Prominent players in the APAC in situ hybridization market include Abbott Laboratories (US), Thermo Fisher Scientific (US), Danaher Corporation (US), Merck (Germany), F. Hoffmann-La Roche (Switzerland), BioView (Israel), Agilent Technologies (US), Biocare Medical (US), Bio-Techne Corporation (US), QIAGEN (Germany), PerkinElmer (US), Enzo Biochem (US), Bio-Rad Laboratories (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), OpGen (US), Bio SB (US), Abcam (UK), Zytomed (Germany), 10x Genomics Inc. (US), and NeoGenomics Laboratories (US).

The consumables accounted for the largest share of the APAC in situ hybridization industry

The APAC in situ hybridization market is segmented into consumables, instruments, and software based on product. In 2021, the ISH consumables segment accounted for the largest share of this market. The growing government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics are expected to drive the growth of the consumables market during the forecast period.

The DNA FISH technology segment dominated the fluorescent APAC in situ hybridization industry

Based on the technology, the APAC in situ hybridization market is FISH (fluorescent in situ hybridization) and CISH (chromogenic in situ hybridization). The FISH segment is further categorized into DNA FISH, RNA FISH, and PNA FISH. In 2021, the FISH segment dominated the market with the highest revenue share as FISH is better for data analysis as FISh offers better visuals on software.

In 2021, hospitals & diagnostic laboratories generated the highest revenue in the APAC in situ hybridization industry.

Based on the end user, the APAC in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. In 2021, the hospital & diagnostic laboratories generated the second highest revenue in the market.The growing patient population, increase in Medicare reimbursements for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.

Japan was the largest market for Asia Pacific in situ hybridization industry in 2021.

Companies in Japan are increasingly focusing on revolutionizing the field of precision oncology and personalized medicine with the integration of genetics and proteomics diagnosis. Several collaborations have been observed in the country, which support the research industry in Japan. This trend is expected to continue in the coming years and contribute to market growth in Japan.

Direct Purchase at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=51341505

To curb the growing incidence of chronic diseases, the Japanese government has been taking initiatives for targeted treatments & personalized therapies, such as the establishment of the Center for Cancer Genomics and Advanced Therapeutics. This initiative is the focal point through which the government aims to aggregate and manage public information on genomic medicine. Efforts like these will also favor market growth in the country.